Successful treatment of asymptomatic or clinically terminal bovine Mycobacterium avium subspecies paratuberculosis infection (Johne's disease) with the bacterium Dietzia used as a probiotic alone or in combination with dexamethasone

References

• Hayee B, Rahman FZ, Sewel G, Smith AM, Segal AW. Crohn's disease as an immunodeficiency. Exper Rev Clin Immunol 2010; 6:585 - 596
   PubMed Web of Science ®Google Scholar
• Lalande JD, Behr MA. Mycobacteria in Crohn's disease: how innate immune deficiency may result in chronic inflammation. Exper Rev Clin Immunol 2010; 6:633 - 641
   PubMed Web of Science ®Google Scholar
• Beisner J, Stange EF, Wehkamp J. Innate antimicrobial immunity in inflammatory bowel diseases. Exper Rev Clin Immunol 2010; 6:809 - 818
   PubMed Web of Science ®Google Scholar
• Siegel CA, Sands BE. Review article: Practical management of inflammatory bowel disease patients taking immunomodulators. Ali Pharm Ther 2005; 22:1 - 16
   PubMed Web of Science ®Google Scholar
• Akobeng AK. Review article: The evidence base for interventions used to maintain remission in Crohn's disease. Ali Pharm Ther 2008; 27:11 - 18
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. New Engl J Med 1997; 337:1029 - 1035
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New Engl J Med 1999; 340:1398 - 1405
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastro 2004; 99:1984 - 1989
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-1 trial. Gastro 2006; 130:323 - 333
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Bolvin M, et al. CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastro 2005; 129:807 - 818
   PubMed Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. New Engl J Med 2003; 348:24 - 32
   PubMed Web of Science ®Google Scholar
• Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54:1121 - 1125
   PubMed Web of Science ®Google Scholar
• Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastro 2008; 103:1428 - 1435
   PubMed Web of Science ®Google Scholar
• Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastro 1994; 94:878 - 883
   Google Scholar
• Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastro 2002; 97:803 - 823
   PubMed Web of Science ®Google Scholar
• Imperato AK, Smiles S, Abramson SB. Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Gastro 2004; 16:199 - 205
   Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. New Engl J Med 2005; 353:362 - 368
   PubMed Web of Science ®Google Scholar
• Reddy JG, Loftus EV Jr. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastro Clin N Am 2006; 35:837 - 855
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arth Rheum 2007; 56:2886 - 2895
   PubMed Web of Science ®Google Scholar
• Blonski W, Lichtenstein GR. Safety of biologic therapy. Inflam Bowel Dis 2007; 13:769 - 796
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflam Bowel Dis 2009; 15:1308 - 1319
   PubMed Web of Science ®Google Scholar
• Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastro 2010; 16:1443 - 1444
   Google Scholar
• Singh JA, Wells GA, Christensen R, Tanjong GE, Maxwell L, MacDonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; 2:CD008794
   PubMed Web of Science ®Google Scholar
• Krok KL, Lichtenstein GR. Nutrition in Crohn's disease. Curr Opin Gastro 2003; 19:148 - 153
   PubMed Web of Science ®Google Scholar
• Drisko J, Bischoff B, Hall M, McCallum R. Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. J Am Col Nut 2006; 25:514 - 522
   PubMed Web of Science ®Google Scholar
• Roberts CL, Keita AV, Duncan SH, O'Kennedy N, Söderholm JD, Rhodes JM, Campbell BJ. Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut 2010; 59:1331 - 1339
   PubMed Web of Science ®Google Scholar
• Borody TJ, Leis S, Warren EF, Surace R. Treatment of severe Crohn's disease using antimycobacterial triple therapy—approaching a cure?. Dig Liver Dis 2002; 34:29 - 38
   PubMedGoogle Scholar
• Sartor RB. Targeting enteric bacteria in treatment of inflammatory bowel diseases: Why, How, and When. Curr Opin Gastro 2003; 19:358 - 365
   PubMed Web of Science ®Google Scholar
• Chamberlin W, Ghobrial G, Chehtane M, Naser SA. Successful treatment of a Crohn's disease patient infected with bacteremic Mycobacterium paratuberculosis. Am J Gastro 2007; 102:1572 - 1575
   Web of Science ®Google Scholar
• Frissora CL, Cash BD. Review article: The role of antibiotics vs. conventional pharmaco-therapy in treating symptoms of irritable bowel syndrome. Ali Pharm Ther 2007; 25:1271 - 1281
   PubMed Web of Science ®Google Scholar
• Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis 2010; 50:473 - 480
   PubMed Web of Science ®Google Scholar
• Lochs H. Antibiotic induces remission of Crohn's disease in phase 2 trial. Presented at 18th Annual United European Gastroenterology Week 2010; Abstract 3075
   Google Scholar
• Elliott DE, Summers RW, Weinstock JV. Helminths as governors of immune-mediated inflammation. Int J Parasitology 2007; 37:457 - 464
   PubMed Web of Science ®Google Scholar
• Elliott DE, Weinstock JV. Helminthic therapy: using worms to treat immune-mediated disease. Adv Exp Med Biol 2009; 666:157 - 166
   PubMed Web of Science ®Google Scholar
• Grainger JR, Smith KA, Hewitson JP, McSorley HJ, Harcus Y, Filbey KJ, et al. Helminth secretions induce de novo T cell Foxp3 expression and regulatory function through the TGF-b pathway. J Exp Med 2010; 207:2331 - 2341
   PubMed Web of Science ®Google Scholar
• O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastro 2005; 128:541 - 551
   PubMed Web of Science ®Google Scholar
• Andresen V, Baumgart DC. Role of probiotics in the treatment of irritable bowel syndrome: Potential mechanisms and current clinical evidence. Intl J Probiot Prebiot 2006; 1:11 - 18
   Google Scholar
• Boirivant M, Strober W. Mechanism of action of probiotics. Curr Opin Gastro 2007; 23:679 - 692
   PubMed Web of Science ®Google Scholar
• Guarino A, Lo Vecchio A, Canani RB. Probiotics as prevention and treatment for diarrhea. Curr Opin Gastro 2009; 25:18 - 23
   PubMed Web of Science ®Google Scholar
• Pagnini C, Saced R, Bamias G, Arseneau KO, Pizarro TT, Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci 2010; 107:454 - 459
   PubMed Web of Science ®Google Scholar
• Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Ped Gastro Nutr 2003; 36:223 - 227
   PubMed Web of Science ®Google Scholar
• Rioux KP, Fedorak RN. Probiotics in the treatment of inflammatory bowel disease. J Clin Gastro 2006; 40:260 - 263
   PubMed Web of Science ®Google Scholar
• Quigley EM. Probiotics in the management of colonic disorders. Curr Gasto Rep 2007; 9:434 - 440
   PubMedGoogle Scholar
• Quigley EM. Probiotics in functional gastrointestinal disorders: what are the facts?. Curr Opin Gastro 2008; 8:704 - 708
   Web of Science ®Google Scholar
• Ligaarden SC, Axelsson L, Naterstad K, Lydersen S, Farup PG. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomized controlled trial. BMC Gastroenterol 2010; 10:16 - 19
   PubMed Web of Science ®Google Scholar
• Bin-Nun A, Bromiker R, Wilschanski M, Kaplan M, Rudensky B, Caplan M, et al. Oral probiotics prevent necrotizing in very low birth weight neonates. J Ped 2005; 147:192 - 196
   PubMed Web of Science ®Google Scholar
• Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, et al. Oral probiotics reduce incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005; 115:1 - 4
   PubMed Web of Science ®Google Scholar
• Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotizing enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials. Lancet 2007; 369:1614 - 1620
   PubMed Web of Science ®Google Scholar
• Thomas DW, Greer FR. Probiotics and prebiotics in pediatrics. Pediatrics 2010; 126:1217 - 1231
   PubMed Web of Science ®Google Scholar
• Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhea. Int Micro 2004; 7:59 - 62
   PubMed Web of Science ®Google Scholar
• Hickson M, D'Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, et al. Use of probiotic Lactobacillus preparation to prevent diarrhea associated with antibiotics: randomized double blind placebo controlled trial. Brit Me J 2007; 335:80
   PubMed Web of Science ®Google Scholar
• Guarino A, Lo Vecchio A, Canani RB. Probiotics as prevention and treatment for diarrhea. Curr Opin Gastro 2009; 25:18 - 23
   PubMed Web of Science ®Google Scholar
• Grandy G, Medina M, Soria R, Teran C, Araya M. Probiotics in the treatment of acute rotavirus diarrhea. A randomized, double-blind controlled trial using two different probiotic preparations in Bolivian children. BMC Infect Dis 2010; 10:253 - 257
   PubMed Web of Science ®Google Scholar
• Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhea. Cochrane Database Syst Rev 2010; 11:CD003048
   PubMed Web of Science ®Google Scholar
• Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999; 354:635 - 639
   PubMed Web of Science ®Google Scholar
• Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: A controlled 6-month intervention. Ali Pharm Therap 2005; 22:387 - 394
   PubMed Web of Science ®Google Scholar
• Borowiec AM, Fedorak RN. The role of probiotics in management of irritable bowel syndrome. Curr Gastro Rep 2007; 9:393 - 400
   PubMedGoogle Scholar
• Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 2007; 66:307 - 315
   PubMed Web of Science ®Google Scholar
• Quigley EM. What is the evidence for the use of probiotics in functional disorders?. Curr Gastro Rep 2008; 10:379 - 384
   PubMedGoogle Scholar
• Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53:108 - 114
   PubMed Web of Science ®Google Scholar
• O'Sullivan GC, Kelly P, O'Halloran S, Collins C, Collins JK, Dunne C, et al. Probiotics: an Emerging therapy. Curr Pharm Des 2005; 11:3 - 10
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Morselli C, Poggioli G, Tambasco R, Calabrese C, et al. High dose probiotics for the treatment of active pouchitis. Dis Colon &; Rectum 2007; 50:2075 - 2078
   Google Scholar
• Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103:1707 - 1715
   PubMed Web of Science ®Google Scholar
• Clarke CJ. The pathology and pathogenesis of paratuberculosis in ruminants and other species. J Comp Path 1997; 116:217 - 261
   PubMed Web of Science ®Google Scholar
• Chiodini RJ, Van Kruiningen HJ, Merkal RS. Ruminant paratuberculosis (Johne's disease): the current status and future prospects. Cornell Vet 1984; 74:218 - 262
   PubMedGoogle Scholar
• Chiodini RJ. Crohn's disease and the mycobacterioses: A review and comparison of two disease entities. Clin Micro Rev 1989; 2:90 - 117
   PubMed Web of Science ®Google Scholar
• Scanu AM, Bull TJ, Cannas S, Sanderson JD, Sechi LA, Dettori G, et al. Mycobacterium avium subsp. paratuberculosis infection in cases of irritable bowel syndrome and comparison with Crohn's disease and Johne's disease: common neural and immune pathogenicities. J Clin Micro 2007; 45:3883 - 3890
   PubMed Web of Science ®Google Scholar
• Whittington RJ, Windsor PA. In utero infection of cattle with Mycobacterium avium subsp. paratuberculosis: A critical review and meta-analysis. Vet J 2009; 179:60 - 69
   PubMed Web of Science ®Google Scholar
• Chiodini RJ. Immunology: resistance to paratuberculosis. Vet Clin N Am Food Anim Pract 1996; 12:313 - 343
   PubMed Web of Science ®Google Scholar
• El-Zaatari FA, Naser SA, Markesich DC, Kalter DC, Engstand L, Graham DY. Identification of Mycobacterium avium complex in sarcoidosis. J Clin Microbiol 1996; 34:2240 - 2245
   PubMed Web of Science ®Google Scholar
• Sechi LA, Rosu V, Pacifico A, Fadda G, Ahmed N, Zanetti S. Humoral immune responses of Type 1 Diabetes patients to Mycobacterium avium subspecies paratuberculosis lend support to the infectious trigger hypothesis. Clin Vaccine Immunol 2008; 15:320 - 326
   PubMed Web of Science ®Google Scholar
• Paccagnini D, Sieswerda L, Rosu V, Masala S, Pacifico A, Gazouli M, et al. Linking chronic infection and autoimmune diseases: Mycobacterium avium subspecies paratuberculosis, SLC11A1 polymorphisms and type-1 diabetes mellitus. PloS One 2009; 9:e7109
   Web of Science ®Google Scholar
• Rani PS, Sechi LA, Ahmed N. Mycobacterium avium subspecies paratuberculosis as a trigger of type-1 diabetes: destination Sardinia, or beyond?. Gut Path 2010; 2:1 - 6
   PubMedGoogle Scholar
• Dow CT, Ellingson JLE. Detection of Mycobacterium avium ss. paratuberculosis in Blau Syndrome tissues. Autoimmun Dis 2010; http://dx.doi.org/10.4061/2010/127692-697
   PubMedGoogle Scholar
• Pierce ES. Ulcerative colitis and Crohn's disease: is Mycobacterium avium subspecies paratuberculosis the common villain?. Gut Path 2010; 2:21
   PubMed Web of Science ®Google Scholar
• Chamberlin WM, Naser SA. Integrating theories of the etiology of Crohn's disease. On the etiology of Crohn's disease; questioning the hypotheses. Med Sci Monit 2006; 12:RA27 - RA33
   PubMed Web of Science ®Google Scholar
• Feller M, Huwiler K, Stephan R, Altpeter E, Shang A, Furrer H, et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7:607 - 613
   PubMed Web of Science ®Google Scholar
• Behr MA, Kapur V. The evidence for Mycobacterium paratuberculosis in Crohn's disease. Curr Opin Gastro 2008; 24:17 - 21
   PubMed Web of Science ®Google Scholar
• Hermon-Taylor J. Mycobacterium avium subspecies paratuberculosis Crohn's disease and the Doomsday scenario. Gut Patho 2009; 1:1 - 15
   PubMedGoogle Scholar
• Richards WD. Milner A R, Wood P R. In vitro and in vivo inhibition of Mycobacterium paratuberculosis by iron deprivation: A hypothesis. Proceedings Conference on Johne's Disease in Australia 1988; MA Int Assoc Paratub Inc Rehoboth 87 - 94
   Google Scholar
• Click RE, Van Kampen CL. Progression of Johne's disease curtailed by a probiotic. J Dairy Sci 2009; 92:4846 - 4851
   PubMed Web of Science ®Google Scholar
• Click RE, Van Kampen CL. Assessment of Dietzia subsp. C79793-74 for treatment of cattle with evidence of paratuberculosis. Virulence 2010; 1:145 - 155
   PubMed Web of Science ®Google Scholar
• Click RE, Van Kampen CL. Comparison of antemortem assays to assess progression-regression of paratuberculosis in individual dairy animals. Virulence 2010; 1:134 - 144
   PubMed Web of Science ®Google Scholar
• Lomborg SR, Agerholm JS, Jensen AL, Nielsen LR. Effects of experimental immune-suppression in cattle with persistently high antibody levels to Salmonella Dublin lipopolysaccharide O-antigens. BMC Vet Res 2007; 3:17 - 24
   PubMedGoogle Scholar
• Slocombe RF. Combined streptomycin-isoniazidrifampin therapy in the treatment of Johne's disease in a goat. Can Vet J 1982; 23:160 - 163
   PubMed Web of Science ®Google Scholar
• St.-Jean G, Jernigan AD. Treatment of infection in ruminates. Vet Clin N Am Food Anim Pract 1991; 7:793 - 804
   PubMed Web of Science ®Google Scholar
• St.-Jean G. Treatment of clinical paratuberculosis in cattle. Vet Clin N Am Food Anim Pract 1996; 12:417 - 430
   PubMed Web of Science ®Google Scholar
• Koets AP, Adugna G, Janss LL, van Weering HJ, Kalis CH, Wentink GH, et al. Genetic variation of susceptibility to Mycobacterium avium subspecies paratuberculosis infection in dairy cattle. J Dairy Sci 2000; 83:2702 - 2708
   PubMed Web of Science ®Google Scholar
• Mortensen H, Nielsen SS, Berg P. Genetic variation and heritability of the antibody response to Mycobacterium avium subspecies paratuberculosis in Danish Holstein cows. J Dairy Sci 2004; 87:2108 - 2113
   PubMed Web of Science ®Google Scholar
• Gonda MG, Chang YM, Shook GE, Collins MT, Kirkpatrick BW. Genetic variation of Mycobacterium avium ssp. paratuberculosis infection in US Holsteins. J Dairy Sci 2006; 89:1804 - 1812
   PubMed Web of Science ®Google Scholar
• Pinedo PJ, Buergelt CD, Donovan GA, Melendez P, Morel L, Wu R, et al. Association between CARD15/NOD2 gene polymorphisms and paratuberculosis infection in cattle. Vet Micro 2009; 134:346 - 352
   PubMed Web of Science ®Google Scholar
• Pinedo PJ, Buergelt CD, Donovan GA, Melendez P, Morel L, Wu R, et al. Candidate gene polymorphisms (BoIFNG, TLR4, SLC11A1) as risk factors for paratuberculosis infection in cattle. Pre Vet Med 2009; 91:189 - 196
   PubMed Web of Science ®Google Scholar
• Gunesh S, Thomas GAO, Williams GT, Roberts A, Hawthorne AB. The incidence of Crohn's disease in Cardiff over the last 75 years: An update for 1996–2005. Ali Pharma Ther 2008; 27:211 - 219
   PubMed Web of Science ®Google Scholar
• Strober W. Inside the microbial and immune labyrinth: Gut microbes: friends or fiends?. Nature Med 2010; 16:1195 - 1197
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response in early but not late pediatric Crohn's disease. Am J Gast 2000; 95:3189 - 3194
   PubMed Web of Science ®Google Scholar
• Lionetti P, Bronzini F, Salvestrini C, Bascietto C, Berni Canani R, De Angelis GL, et al. Response to infliximab is related to disease duration in pediatric Crohn's disease. Ali Pharma Ther 2003; 18:425 - 432
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel JF, Panes J. Recent onset Crohn's disease shows higher remission rates and durability of response to treatment with subcutaneous monthly certolizumab pegol: Results from the analysis of the PRECISE 2 Phase III study. Gut 2006; 55:A131
   PubMed Web of Science ®Google Scholar
• Panaccione R. Top-down vs. Step-up therapy in Crohn's Disease: What does the evidence say?. Medscape Gastro 2007; view article/560005
   Google Scholar
• Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastro 2007; 132:863 - 873
   PubMed Web of Science ®Google Scholar
• Schreiber S, Reinisch W, Colombel JF. Early Crohn's disease shows high levels of remission to therapy with adalimumab: Sub-analysis of CHARM. Gastro 2007; 132:suppl 2 A985
   Google Scholar
• Sepehri S, Kotlowski R, Bernstein CN, Krause DO. Microbial diversity of inflamed and non-inflamed gut biopsy tissues in inflammatory bowel disease. Inflam Bowel Dis 2007; 13:675 - 683
   PubMed Web of Science ®Google Scholar
• Behr MA. The path to Crohn's disease : is mucosal pathology a secondary event?. Inflamm Bowel Dis 2010; 16:896 - 902
   PubMed Web of Science ®Google Scholar
• Pineton de Chambrun G, Colombel JF, Poulain D, Darfeuille-Michaud A. Pathogenic agents in inflammatory bowel diseases. Curr Opin Gastro 2008; 24:440 - 447
   PubMed Web of Science ®Google Scholar
• Barnich N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli and Crohn's disease. Curr Opin Gastro 2007; 23:16 - 20
   PubMed Web of Science ®Google Scholar
• Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME Journal 2007; 1:403 - 418
   PubMed Web of Science ®Google Scholar
• Kotlowski R, Bernstein CN, Sepehri S, Krause DO. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 2007; 56:669 - 675
   PubMed Web of Science ®Google Scholar
• Ohkusa T, Sato N, Ogihara T, Morita K, Ogawa M, Okayasu I. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastro Hepatol 2002; 17:849 - 853
   PubMed Web of Science ®Google Scholar
• Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al. Mucosal flora in inflammatory bowel disease. Gastro 2002; 122:44 - 54
   PubMed Web of Science ®Google Scholar
• Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastro 2004; 127:80 - 93
   PubMed Web of Science ®Google Scholar
• Posserud I, Stotzer PO, Bjornsson ES, Abrahamsson H, Simren M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007; 56:802 - 808
   PubMed Web of Science ®Google Scholar
• Othman M, Aguero R, Lin HC. Alterations in intestinal microbial flora and human disease. Curr Opin Gastro 2008; 24:11 - 16
   PubMed Web of Science ®Google Scholar
• Sartor RB. Bacteria in Crohn's disease: mechanisms of inflammation and therapeutic implications. J Clin Gastroenterol 2007; 41:S37 - S43
   PubMed Web of Science ®Google Scholar
• Thompson NP, Montgomery SM, Wadsworth ME, Pounder RE, Wakefield AJ. Early determinants of inflammatory bowel disease: use of two national longitudinal birth cohorts. Eur J Gastro Hepatol 2000; 12:25 - 30
   PubMed Web of Science ®Google Scholar
• Baron S, Turck D, Leplat C, Merle V, Gower-Rousseau C, Marti R, et al. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut 2005; 54:357 - 363
   PubMed Web of Science ®Google Scholar
• Asakura H, Suzuki K, Kitahora T, Morizane T. Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis?. J Gastro Hepatol 2008; 23:1794 - 1801
   PubMed Web of Science ®Google Scholar
• Markowitz J, Kugathasan S, Dubinsky M, Mei L, Crandall W, LeLeiko N, et al. Age of diagnosis influences serologic response in children with Crohn's disease: a possible clue to etiology?. Inflam Bowel Dis 2009; 15:714 - 719
   PubMed Web of Science ®Google Scholar
• Chamberlin W, Graham DY, Hulten K, El-Zimaity HMT, Schwartz MR, Naser S, et al. Review article: Mycobacterium avium subsp. paratuberculosis as one cause of Crohn's disease. Ali Pharm Ther 2001; 15:337 - 346
   PubMed Web of Science ®Google Scholar
• Chamberlin WM, Shafran I. Anti-mycobacterials and Crohn's disease. Ali Pharm Ther 2008; 28:373 - 374
   Web of Science ®Google Scholar
• Wehkamp J, Stange EF. A new look at Crohn's disease: breakdown of the mucosal antibacterial defense. Ann N Y Acad Sci 2006; 1072:321 - 331
   PubMed Web of Science ®Google Scholar
• De Bortoli N, Leonardi G, Ciancia E, Merlo A, Bellini M, Costa F, et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastro 2007; 102:951 - 956
   PubMed Web of Science ®Google Scholar
• Baron M. A patented strain of Bacillus coagulans increased immune response to viral challenge. Postgrad Med 2009; 121:114 - 118
   PubMed Web of Science ®Google Scholar
• Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastro 2005; 21:44 - 50
   PubMed Web of Science ®Google Scholar
• Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006; Art. No. CD004826
   Web of Science ®Google Scholar
• Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomized controlled trial with Lactobacillus GG. Gut 2002; 51:405 - 409
   PubMed Web of Science ®Google Scholar
• Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomized, double blind, placebo controlled GETAID trial. Gut 2006; 55:842 - 847
   PubMed Web of Science ®Google Scholar
• Naser SA, Ghobrial G, Romero C, Valentine JF. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet 2004; 364:1039 - 1044
   PubMed Web of Science ®Google Scholar
• Juste RA, Elguezabal N, Pavon A, Garrido JM, Geijo M, Sevilla I, et al. Association between Mycobacterium avium subspecies paratuberculosis DNA in blood and cellular and humoral immune response in inflammatory bowel disease patients and controls. Intl J Infect Dis 2009; 13:247 - 254
   PubMed Web of Science ®Google Scholar
• Whitlock RH, Buergelt C. Preclinical and clinical manifestations of paratuberculosis (including pathology). Vet Clinic N Am Food Anim Pract 1996; 12:345 - 356
   PubMed Web of Science ®Google Scholar
• Woese CR. Bacterial evolution. Microbiol Rev 1987; 51:221 - 271
   PubMedGoogle Scholar
• Cukovic-Cavka S, Vermeirem S, Hrstic I, Claessens G, Kolacek S, Jakic-Cazumovic J, et al. NOD2/CARD15 mutations in Croatian patients with Crohn's disease: prevalence and genotype-phenotype relationship. Eur J Gastro Hep 2006; 18:895 - 899
   PubMed Web of Science ®Google Scholar
• Gui GPH, Thomas PRS, Tizard MLV, Lake J, Sanderson JD, Hermon-Taylor J. Two-year Outcomes: analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicro Chemother 1997; 39:393 - 400
   PubMed Web of Science ®Google Scholar
• Grehan MJ, Borody TJ, Leis SM, Campbell J, Mitchell H, Wettstein A. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastrol 2010; 44:551 - 561
   PubMed Web of Science ®Google Scholar